Previously Untreated, Locally Advanced, Inoperable

Previously Untreated, Locally Advanced, Inoperable

April 19, 2024

A Randomized, Open-label, Phase 3 Study of Sacituzumab Govitecan Versus
Treatment of Physician’s Choice in Patients With Previously Untreated, Locally
Advanced, Inoperable or Metastatic Triple-Negative Breast Cancer Whose Tumors
Do Not Express PD-L1 or in Patients Previously Treated With Anti-PD-(L)1 Agents
in the Early Setting Whose Tumors Do Express PD-L1

Schedule an Appointment

Select an appointment date and time from available spots listed below.